News & Topics

2014.08.04 ReproCELL Expects Synergy and Business Benefits through the Acquisitions of Reinnervate and BioServe

ReproCELL Expects Synergy and Business Benefits through the Acquisitions of Reinnervate and BioServe

2014.07.08 ReproCELL Inc. announces business collaboration with KOKEN CO., LTD

Yokohama, Kanagawa, Japan ReproCELL Inc. (ReproCELL, CEO: Chikafumi Yokoyama, Ph.D. JASDAQ: 4978) announced today that ReproCELL has completed a distributorship agreement with KOKEN CO., LTD (KOKEN, Tokyo, Japan, President: Yuzo Tarumi, Ph.D.). ReproCELL will sell KOKEN’s collagen products globally outside Japan. In the half century since founding in 1959, KOKEN has become a world-class specialist in the development and manufacture of silicone materials to replace human skin and other parts of the body, along with various types of medical plastics, life simulation models for medical education, and Atelocollagen products ranging from cosmetics to medical-use materials. ReproCELL will promote KOKEN’s tissue/cell culture collagen products, AteloCell® including 3D tissue/cell culture scaffolds and […]

2014.07.08 ReproCELL supports CTSI Stem Cell Core Retreat on Jul 21, 2014.

ReproCELL supports CTSI Stem Cell Core Retreat as an official sponsor on Jul 21, 2014. – Flyer – Program

2014.06.30 Application to the ReproCELL’s Innovative Research Grant Program 2014 is closed on June 30, 2014.

Application to the ReproCELL’s Innovative Research Grant Program 2014 is closed on June 30, 2014.

2014.01.28 ReproCELL, Inc., Shinsei Bank to establish joint venture fund

ReproCELL, Inc., Shinsei Bank to establish joint venture fund 1 billion JPY to target unlisted iPS cell and regenerative medical bio-venture within and outside Japan. Click here for more information.

2014.01.28 ReproCELL, Inc. announces the establishment of a subsidiary

The new subsidiary will accelerate R&D efforts and enhance our competitiveness in iPS cell and regenerative medicine segment, thereby contributing to future drug discovery and healthcare business generation. Click here for more information.

2013.12.24 Distributorship agreement with Laboratorios Conda in Spain

Click here for more information.

2013.11.25 Web server maintenance, 12:00 PM to 6:00 PM Dec. 2nd (EST)

Access trouble to our website may cause due to Web server maintenance, 12:00 PM to 6:00 PM Dec. 2nd (EST). If the trouble happens, please contact info_en@reprocell.com We apologize any inconvenience and appreciate your understanding.

2013.11.11 PRODUCTReproCELL Inc. announces the launch of “ReproUNUS”, tailor-made human iPS cell derived disease model cells.

Yokohama, Kanagawa, Japan – ReproCELL Inc. (ReproCELL, CEO: Chikafumi Yokoyama, Ph.D. JASDAQ: 4978) announced today the upcoming launch of“ReproUNUS”in November, 2013. ReproUNUS is a tailor-made human iPS cell derived disease model developed in collaboration with Takara Bio Inc. (Takara, Shiga, Japan, President: Koichi Nakao, TSE Mothers: 4974). With the launch of RepoUNUS, ReproCELL will be able to customize human iPS cells to a customer’s specific request. The product is a combination of human iPS cell development expertise provided by ReproCELL, and novel gene editing techniques from Takara. Genes of interest vary by customer such as pharmaceutical companies and academic research institutes. ReproCELL can cover those different interests by offering tailor-made […]

2013.11.05 PRODUCTReproCELL Inc. announces the launch of “ReproHSC”, culture medium for human hematopoietic stem cells

Yokohama, Kanagawa, Japan – ReproCELL Inc. (ReproCELL, CEO: Chikafumi Yokoyama, Ph.D. JASDAQ: 4978) announced today that the company will launch “ReproHSC”, culture medium for human hematopoietic stem cells co-developed with Nissan Chemical Industries, LTD (Tokyo, Japan, President: Kojiro Kinoshita) in December, 2013. The company will begin offering samples of “ReproHSC” in November, 2013. Hematopoietic stem cells, found in bone marrow and cord blood, can be differentiated into many cell types such as erythrocytes, leukocytes, and blood platelets. While hematopoietic stem cell transplant (bone marrow transplant / cord blood transplant) has been utilized as an effective method of therapy for diseases such as leukemia, chronic myelodysplastic syndrome, and aplastic anemia, there […]